Combined with the administration’s erratic regulation and policymaking, it threatens to undo the salutary ecosystem that made ...

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day. This change lagged the S&P 500's daily loss of 1.51%. On the other hand, the Dow registered ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

As the pandemic tailwind fades, both Pfizer (PFE) and Moderna (MRNA) have posted financial results that have disappointed investors. Yet, facing the same headwinds, these two companies ...

Pfizer (PFE 1.60%) and Moderna (MRNA 1.89%) were both leaders in the coronavirus vaccine market. However, as sales of these ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.

Few corporate cautionary tales are as vivid as the rise and fall of Moderna Inc. During the pandemic, the company’s mRNA vaccine was approved and distributed in record time, saving ...

The ruling dealt a significant setback for the reduced childhood vaccination schedule championed by Kennedy, a longtime anti-vaccine activist.

Few corporate cautionary tales are as vivid as the rise and fall of Moderna Inc. During the pandemic, the company’s mRNA vaccine was approved and distributed in record time, saving millions of lives ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the Centers for Disease Control. But the field of cancer vaccines, which can be ...